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Abstract
Optimal chemotherapy protocols for high-risk mast cell tumours (MCTs) are unknown. The purpose of this
study was to determine the tolerability and toxicity profile of a rapidly escalating vinblastine and prednisolone
protocol (VPP) in which 3.00 mg/m2 was administered once 7 days apart: at day 14 and at day 21. Dogs with
chemotherapy-na€ıve MCTs presenting to the Oncology Service of a single institution were prospectively
enrolled to receive escalating vinblastine, and haematology and a standardised quality-of-life questionnaire
were assessed prior to each dosage. Thirty-four dogs were included: 30 with microscopic disease treated with
adequate local therapy and four with macroscopic disease. Of 220 doses of vinblastine administered, 4% were
associated with grade 3 and 4 toxicity. A total of 70% of dogs tolerated 3.00 mg/m2 given 7 days apart at day
14 and 21, although 29% of dogs developed dose-limiting toxicities and 8% discontinued the protocol due to
toxicity. In conclusion, VPP was well-tolerated overall, although prior to further dose intensity optimisation, it
is important to determine if dose intensity is linked to outcome in canine MCT to avoid unwarranted toxicity.
Keywords: Oncology, Chemotherapy, Vinblastine, Mast cell tumour.
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Introduction
Mast cell tumours (MCTs) represent one of the most
common tumours in the dog, accounting for 16–21%
of all cutaneous tumours (Bostock 1986). MCTs are
heterogeneous in nature with marked variation in
biological behaviour (Patnaik et al. 1984). Current
treatment paradigms suggest that adequate local
treatment with surgery or a combination of surgery
and definitive intent radiation therapy (RT) is the
treatment of choice, although adjuvant systemic
treatment is commonly recommended for high-risk
MCTs (Blackwood et al. 2012). High-risk MCTs are
commonly considered to include grade III Patnaik
tumours, high grade Kiupel tumours, recurrent
MCTs, ≥stage II tumours or tumours arising in speci-
fic locations (such as scrotum or mucous membranes)
(Baginski et al. 2014; Blackwood et al. 2012;
Cahalane et al. 2006b; Murphy et al. 2006; Patnaik
et al. 1984; Sfiligoi et al. 2005; Thamm et al. 2006).
Vinblastine is a vinca-alkaloid extracted from the
periwinkle plant (Catharanthus roseus) (Golden &
Langston 1988; Rowinsky 2011; William et al. 1975).
It is cell cycle specific and binds tubulin to inhibit
microtubule formation during mitosis (Golden &
Langston 1988; Rowinsky 2011; William et al. 1975).
The dose-limiting toxicity (DLT) of vinblastine is
neutropenia, with a neutrophil nadir occurring
approximately 1 week after drug administration
(Golden & Langston 1988; Rowinsky 2011; William
et al. 1975). In veterinary medicine, although efficacy
has been demonstrated for various types of neo-
plasia, it is most often used as adjunctive treatment
for canine MCTs (Arnold et al. 2011; Bailey et al.
2008; Crow 1977; Davies et al. 2004; Rassnick et al.
2008; Singh et al. 1996; Thamm et al. 1999, 2006; Tru-
mel et al. 2005; Vickery et al. 2008). Vinblastine can
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be prescribed either as a single agent when local
treatment is not an option, or as adjuvant systemic
therapy to adequate local control in high-risk canine
MCTs (Crow 1977; Davies et al. 2004; Rassnick et al.
2008; Thamm et al. 1999, 2006; Trumel et al. 2005;
Vickery et al. 2008).
Chemotherapy is generally dosed near each drug’s
maximally tolerated dose in order to optimise
tumour cell kill (Frei & Canellos 1980; Madewell &
Theilen 1979). Previous work has demonstrated the
importance of dose–response relationships and dose
intensity, defined as chemotherapy dose per unit
time, in improving the outcomes of cancer (Budman
et al. 1998; Chabner 2011; Frei & Canellos 1980;
Kwak et al. 1990; Loibl et al. 2011; Lyman 2009; Nor-
ton 1997; Wudhikarn et al. 2015). For tumours con-
sidered potentially curable in humans, there is
convincing evidence supporting the relevance of
delivered dose intensity, and it has been suggested
that dose intensity is a quality of care indicator in
clinical oncology (Lyman 2009; Norton 1997). In
canine lymphoma, dogs which developed grade 3 or
4 neutropenia following chemotherapy demonstrated
improved outcomes, raising the possibility that more
appropriate individual dosing was administered (Sor-
enmo et al. 2010; Vaughan et al. 2007).
A commonly used and well-tolerated protocol in
dogs with high grade or metastatic MCTs, which was
initially empirically extrapolated without phase I
data in dogs, consists of eight doses of vinblastine at
a dosage of 2 mg/m2. The first four doses are given
weekly, followed by four doses given every other
week (Crow 1977; Davies et al. 2004; Rassnick et al.
2008; Thamm et al. 1999, 2006; Trumel et al. 2005;
Vickery et al. 2008). Prednisolone is administered
concurrently, as it significantly enhances efficacy
compared to vinblastine alone (Stanclift & Gilson
2008). One study evaluating this protocol reported
severe adverse effects in only 5% of dogs, suggesting
that dogs may tolerate a higher dosage of vinblastine
(Thamm et al. 1999). In the last decade, several stud-
ies have attempted a dosage optimisation for vin-
blastine in dogs.
In a phase I dose escalation trial of vinblastine, the
maximally tolerated dose for vinblastine was
3.50 mg/m2 every other week. However, grade 4
toxicity, as graded according to Veterinary Coopera-
tive Oncology Group Common Terminology Criteria
for Adverse Effects v 1.1 (VCOG CTCAE), was
common (Bailey et al. 2008; Veterinary cooperative
oncology group, 2011). Notably, of 26 dogs that
received vinblastine at 3.50 mg/m2 in a subsequent
study, 46% developed grade 4 neutropenia and two
dogs presented with febrile neutropenia despite the
use of prophylactic antibiotics (Rassnick et al. 2008).
The intended dose intensity of that protocol was
1.94 mg/m2/week; however, dose intensity in the first
4 weeks (1.75 mg/m2/week) was lower than that in
the first 4 weeks of the traditional vinblastine proto-
col using a dosage of 2.00 mg/m2 (2 mg/m2/week)
(Rassnick et al. 2008).
In a separate strategy to increase the dose intensity
in canine MCTs, a dose-escalating vinblastine-pre-
dnisolone protocol provided a starting dosage of
2.00 mg/m2 that escalated in weekly increments to
2.33 mg/m2, 2.67 mg/m2 and 3.00 mg/m2 followed by
four doses at 3.00 mg/m2 every other week, with an
intended dose intensity of 1.83 mg/m2/week (Vickery
et al. 2008). Of 24 dogs treated, only three dogs
(12.5%) required dose reductions during the proto-
col, and fewer than 10% of vinblastine administra-
tions at 2.67 mg/m2 or 3.00 mg/m2 were associated
with grade 3 or 4 toxicity (Vickery et al. 2008).
The current prospective study was undertaken in
an attempt to further optimise dose intensity with a
rapidly escalating vinblastine protocol (VPP), shown
in Table 1, in which vinblastine was escalated from
2.30 mg/m2 weekly such that 3.00 mg/m2 was given
7 days apart once, at day 14 and day 21, prior to
Table 1. Rapid escalation vinblastine-prednisolone protocol (VPP)
involving eight planned doses of vinblastine
Day Vinblastine
(mg/m2)
Prednisolone
(mg/kg SID)
0 2.3 1
7 2.6 1
14 3 0.5
21 3 0.5
35 3 0.5
49 3 0.5
63 3 0.5
77 3 0.5
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continuing a standard every other week administra-
tion with a dosage of 3.00 mg/m2 for the latter half of
the protocol. VPP was designed as an interim step to
assess the tolerability of vinblastine given weekly at
one point in the protocol prior to instituting weekly
vinblastine at 3.00 mg/m2. The primary hypothesis
was that VPP would be well tolerated in dogs with
MCTs with fewer than 20% DLTs as defined by
grade 3 gastrointestinal toxicities or grade 4 neu-
tropenias. While arbitrarily chosen, 20% was consid-
ered acceptable for continued optimisation of the
protocol, and therefore was selected as a defined
endpoint. The occurrence of greater than 20% DLTs
was deemed unacceptable and would require alter-
ation of the protocol to reduce toxicities. The pri-
mary objective of the study was to determine the
toxicity profile of VPP.
Materials and methods
Dogs
Chemotherapy-na€ıve client-owned dogs that were
referred to the Oncology Department of the Hospital
for Small Animals of the Royal (Dick) School of
Veterinary Studies with cytologically or histopatho-
logically confirmed MCTs from February 2013 to July
2015, and with clinical indication for receiving
chemotherapy, were eligible to receive VPP. The clin-
ical protocol and data collection were approved by
the institutional Veterinary Ethics and Review Com-
mittee. Chemotherapy was used as an adjuvant treat-
ment to local therapy in dogs with high-risk MCTs or
as a sole or adjuvant therapy for dogs in which ade-
quate local treatment was not feasible or declined. A
‘high-risk’ MCT was defined as a MCT with at least
one of the following negative prognostic factors: high
grade (Patnaik or Kiupel), present in a high-risk loca-
tion (mucosal, preputial or scrotal), recurrence and/or
documented locoregional or distant metastases. Dogs
with distant metastasis were eligible to be included.
Dogs with ‘high risk’ subcutaneous MCTs could also
be included. Although there is not a reliable grading
scheme for subcutaneous or mucosal MCTs, Kiupel
grading criteria was applied by a pathologist in these
tumours in order to provide some measure of
histologic features of malignancy (Kiupel et al. 2011).
Dogs with completely excised MCTs were defined as
those in which ≥3 mm radially and at least one fascial
plane deep tumour-free margins were obtained.
Incomplete excision was defined as <1 mm of margin
histologically. All others were considered narrowly
excised (1–3 mm of margin). For dogs with narrowly
excised or incompletely excised high-risk MCTs, revi-
sion surgery and/or definitive-intent RT with photons
or electrons was recommended. All radiation treat-
ments were prescribed by a radiation oncologist
board-certified by the American College of Veteri-
nary Radiology (ACVR) and administered by a
licensed radiation therapist. Radiation-induced acute
toxicity was monitored with routine weekly rechecks
until resolution, and graded according to the Veteri-
nary Radiation Therapy Oncology Group acute radi-
ation morbidity scoring scheme (Ladue & Klein
2001). In dogs with microscopic disease, chemother-
apy with or without concurrent RT was initiated fol-
lowing recovery from surgery.
All dogs underwent clinical staging prior to start-
ing chemotherapy, consisting of a full physical exami-
nation, complete blood count (CBC), serum
biochemistry profile, fine needle aspirate of regional
lymph nodes if accessible, three-view thoracic radio-
graphs and abdominal ultrasound. In dogs with high-
risk MCTs, routine fine needle aspirate of liver and
spleen were performed regardless of their ultrasono-
graphic appearance when possible. Ki67 expression
was not determined. Exclusion criteria included dogs
with a suggestion of significant bone marrow dysfunc-
tion (assessed with a CBC), inadequate performance
status [Modified Eastern Cooperative Oncology
Group (ECOG) constitutional performance score >
1], concurrent diseases requiring immunosuppressive
therapy (i.e. severe atopy, immune-mediated disease)
other than prednisolone and concurrent systemic
anti-neoplastic treatment (Oken et al. 1982). Dog
and tumour characteristics, including signalment,
clinical and histopathologic features, were recorded.
Treatment and toxicity assessment
VPP is described in Table 1. Dogs with macroscopic
disease were concurrently treated with gastro-
© 2016 The Authors. Veterinary Medicine and Science Published by John Wiley & Sons Ltd.
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protectant therapy (a proton pump inhibitor) as well
as a systemic histamine blocker.
A complete physical examination was performed
and both CBC and standardised quality-of-life ques-
tionnaire (Fig. 1) were assessed prior to each dosage
of chemotherapy. The decision to perform a CBC at
weeks 5, 7, 9, 11 and 13 (1-week post vinblastine)
was clinician-dependent and varied among dogs. All
toxicities were graded according to VCOG CTCAE
v1.1 and the quality-of-life questionnaire aided in
ensuring all side effects reported by the owner were
documented and graded (Stanclift & Gilson 2008).
The following were considered DLTs: grade 4 neu-
tropenia, ≥ grade 3 thrombocytopenia, ≥ grade 3 gas-
trointestinal toxicity or any neutropenia that caused
a dose delay. Neutrophil and platelet counts were
required to be ≥1.5 9 109 neutrophils/l (1500/lL)
and ≥ 50 9 109 platelets/l (50 000/lL), respectively,
immediately prior to vinblastine administration. Vin-
blastine dose reductions of 10% were calculated fol-
lowing the occurrence of any DLT. Subsequent to a
dose delay associated with neutropenia or thrombo-
cytopenia, a CBC was reassessed 1–3 days after
delay. Dose escalation was permitted in the protocol
following early dose reduction and was performed in
5% dose increments. Grade 2 gastrointestinal toxici-
ties were managed with supportive care if sponta-
neous resolution did not occur and/or when clients
deemed effects intolerable. Maropitant was used as a
first-line medication for vomiting, nausea or
decreased appetite, and metronidazole was used as a
first-line medication for colitis.
Date: 
Owners name: 
Animals name: 
Case number: 
Please fill in this sheet to keep us up to date with your pet’s progress. This does not take the place of a  
full clinical examination.  
How has your pet’s mood been since your last visit?
Any changes in attitude or behaviour?                Yes     No 
Has your pet been interacting with other pets and the family?   Yes     No 
Has your pet’s appetite increased or decreased since your last visit?   Yes     No 
Any problems chewing or swallowing?   Yes     No 
Has there been any vomiting?   Yes     No 
Any diarrhoea, constipation, straining or blood in the faeces?   Yes     No 
Has your pet’s drinking changed since your last visit?   Yes     No 
Does your pet wet the house or bed or need to go out at night?                                       Yes     No 
Have you noticed any blood or discolouration in the urine?   Yes     No 
Have you noticed any discharge from the eyes, nose or vagina?   Yes     No 
Any coughing, sneezing or difficulty breathing?   Yes     No 
Have you seen any new lumps or bumps?   Yes     No 
Has your pet lost or gained weight?   Yes     No 
Does your pet rest and sleep well?   Yes     No 
Do you think your pet has any pain or discomfort?   Yes     No 
Has your pet been keen and able to exercise or play since your last visit?   Yes     No 
How would you rate your pet’s overall quality of life at present from 1 - 10?                                      /10 
What medication is your pet on at the moment? 
Are you managing to give this medication successfully? 
Do you need any medications made up today? 
Is there anything else that you think we should know, or is there anything else about your pet’s health that you 
would like to discuss? 
Fig. 1 “Quality-of-life” form.
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Statistical analysis
Statistical analyses were performed by a statistician
(IH) using the R Statistical System (R Core Team,
2015). Initial univariable analysis was performed on
the following variables, which were evaluated as pos-
sible predictors of toxicity or tolerability of 3.00 mg/
m2 administered 7 days apart at days 14 and 21: age,
weight, sex, neuter status, stage, Patnaik grade, Kiu-
pel grade, margin status, mitotic index (MI) and con-
current RT. Dichotomous variables were evaluated
via Fisher’s exact test, while the numerical variables
were evaluated via Mann–Whitney test. Variables
with a univariable P ≤ 0.2 were entered into a multi-
variable binary logistic regression model to assess
potential confounding and allow estimation of a cor-
rected strength of association between predictive fac-
tor and outcome conditional on other factors. Where
data were missing in factors for multi-variable mod-
elling, a subset dataset of complete observations on
variables of interest was used. The multi-variable
models were simplified to minimise Akaike’s Infor-
mation Criteria (AIC) – a parameter count penalised
measure of model fit. A P ≤ 0.05 was considered sta-
tistically significant for reporting of final variables
from the models. The study involved multiple com-
parisons and hypothesis tests. No explicit corrections
are made for this and P-values from hypothesis tests
are presented as is.
Results
Dog and tumour characteristics
Thirty-four dogs were enrolled in the study. Clinical
characteristics for all dogs are listed in Table 2. Med-
ian age at the time of first dose of vinblastine was
6 years, and median weight was 24.8 kg. Three dogs
weighed less than 10 kg.
A diagnosis of MCT was achieved histopathologi-
cally in 33 dogs and cytologically in one dog. In all
cases where histopathology was available, tumours
were graded via the Patnaik and/or Kiupel grading
system. The median MI for all tumours was 1 (range:
0–39). Multiple pathologists in several laboratories
evaluated biopsy specimens. Histopathological
margins were evaluated in all cases where surgery
was performed (30 dogs; Table 3). Complete margins
were achieved in 17 dogs (56.6%), incomplete mar-
gins were achieved in 11 dogs (36.6%) and narrow
margins were achieved in two dogs (6.6%).
Tumour characteristics at the time of
chemotherapy initiation are provided in Table 3.
Twenty-nine dogs had high-risk MCTs and
received VPP as a first-line adjuvant treatment for
microscopic disease. Eight dogs received concur-
rent definitive-intent RT. One dog received VPP
for potential improved local control of an incom-
pletely excised Kiupel low-grade subcutaneous
MCT after declining RT. Three dogs received VPP
as treatment for multifocal macroscopic disease,
and one dog with a high-risk MCT received four
doses of cytoreductive chemotherapy followed by
definitive intent RT concurrently with the remain-
ing doses of vinblastine.
Out of the dogs with high-risk MCTs, several dogs
had multiple factors associated with aggressive dis-
ease: three dogs with grade 3 MCTs, one dog with a
scrotal MCT, one dog with splenic and hepatic
metastases and one dog with diffuse macroscopic
cutaneous MCT (two of which were recurrent) had
concurrent regional lymph node metastasis. All dogs
Table 2. Characteristics of the 34 dogs treated with VPP
Median age (range) 6 years (1–12 years)
Median weight (range) 24.8 kg (7.2–48.6 kg)
Sex
Male neutered 12
Female neutered 14
Male intact 4
Female intact 4
Breed
Labrador Retriever 12
Mixed Breed 4
Springer Spaniel 3
Boxer 3
Weimaraner 2
Stafford Bull Terrier 2
Jack Russell Terrier 2
Lhasa Apso 1
Native American Indian 1
Pug 1
Rottweiler 1
Scottish Terrier 1
Shar Pei 1
© 2016 The Authors. Veterinary Medicine and Science Published by John Wiley & Sons Ltd.
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with lymph node metastasis had at least one meta-
static lymph node confirmed histopathologically.
Treatment
Of the nine dogs that received RT, three were trea-
ted with conformal RT utilising computerised treat-
ment plans (Eclipse, Varian Medical Systems, Palo
Alto, CA) while the remainder were manually
treated with 6–12 MeV electrons (n=3) or 6 MV pho-
tons (n=3). Five dogs with confirmed metastatic
lymph nodes that had been surgically removed had
regional lymph node beds irradiated in conjunction
with the primary MCT site. Radiation was prescribed
to the planning target volume (PTV) in all cases; the
radiation prescription consisted of 48 Gy in seven
dogs, with six dogs prescribed 16 fractions of 3 Gy
and one dog prescribed 15 fractions of 3.2 Gy. Two
dogs were prescribed 18 fractions of 2.8 Gy to
48.6 Gy due to dose-limiting normal tissues adjacent
to the surgical sites. For conformal treatments, the
clinical target volume (CTV) was defined by post-
surgical changes evident on CT with a 5 mm margin
in all directions unless a natural barrier was present.
The PTV was expanded from the CTV by 3 mm in
all directions. For manual photon and electron plans,
the CTV included 2.5 cm of margins to account for
non-visible/non-palpable microscopic disease and the
PTV included an additional margin of 0.5 cm where
possible. Seven of nine dogs developed grade 3 radi-
ation-induced skin toxicity, while two dogs devel-
oped grade 2 radiation-induced skin toxicity; all
resolved within 3 weeks of completion of RT.
A total of 220 treatments of vinblastine were
administered with a median dosage of 3.00 mg/m2
(range: 2.00–3.00 mg/m2); the median number of
doses administered to each dog was 8 (range: 1–8).
Despite the intended dosages in the protocol, vari-
able doses administered as adverse events caused
dose adjustments (Table 4). Twenty-four of the 34
dogs initially enrolled (70%) tolerated 3.00 mg/m2
administered at day 14 and 21.
Eight dogs (23.5%) required dose reductions,
although 11 dogs (32%) would have required dose
reductions had treatment not been discontinued in
three dogs that developed DLT. Six of the eight dogs
that required dose reductions were subsequently
escalated by 5% increments in the dosage at each
dose. One dog developed an additional DLT at
2.20 mg/m2, while the remaining five dogs tolerated
dose escalations well. One dog was escalated to
3.0 mg/m2.
Twenty-three dogs (68%) completed the 12-week
protocol. In total, 24 dogs tolerated 3.00 mg/m2
administered at days 14 and 21 with 17 dogs
Table 3. Individual mast cell tumour characteristics in the 34 dogs
that received VPP
MCT Characteristics Number
Macroscopic MCT 4
Diffuse, grade 3 high grade,
recurrent, regional metastases, MI > 5
1
Diffuse, grade 1–2 low grade 1
Unknown grade – cutaneous, visceral metastases 1
Unknown grade – nasal mucosa 1
Microscopic MCT 30
Subcutaneous high grade MCT 2
Regional metastases 1
Recurrent 1
Incomplete excision 2
Subcutaneous low grade MCT 3
Regional metastasis 2
Complete excision 1
Incomplete excision 2
Cutaneous grade 3 MCT 7
MI >5 5
Regional metastases 2
Recurrent 1
Complete excision 4
Incomplete excision 3
Cutaneous grade 2 high grade MCT 3
Regional metastases 3
Visceral metastases 1
Recurrent 1
Complete excision 1
Narrow excision 1
Incomplete excision 1
Cutaneous grade 2 low grade MCT 11
Regional metastases 9
Recurrent 2
Complete excision 9
Narrow excision 1
Incomplete excision 1
High-risk location 4
Nasal mucosa high grade 1
Oral mucosa low grade 2
Scrotal grade 2 low grade with regional metastases 1
Complete excision 2
Incomplete excision 2
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completing the protocol at the planned dosages and
schedule. The remaining seven dogs required proto-
col alterations in the latter half of the protocol: two
dogs developed DLT, one dog was dose-reduced at
the client’s request following grade 2 gastrointestinal
toxicity, three3 dogs developed progressive disease
and discontinued VPP and one dog terminated treat-
ment early at the client’s request following possible
vinblastine extravasation, although extravasation was
not confirmed and an extravasation reaction did not
develop. Ten dogs did not receive 3.00 mg/m2 on day
14 and 21 for variable reasons: eight dogs developed
DLT earlier in the protocol, while two dogs had pro-
gressive disease after the first dose of vinblastine and
were therefore not escalated.
Toxicity
Neutropenia was the primary DLT and occurred
across multiple dosages (Table 4). A total of 11 epi-
sodes of dose-limiting neutropenia occurred: one epi-
sode following a dosage less than 2.30 mg/m2, seven
episodes following dosages between 2.30 and
3.00 mg/m2 and two episodes following administra-
tion of 3.00 mg/m2. Five of these episodes caused
dose delay, therefore negatively impacted the
intended dose intensity. In four dogs that discontin-
ued the protocol early, four additional dose delays
would have occurred if affected dogs had continued
VPP. None of the other dogs in the study required a
dose delay for any other reasons.
Four dogs (12%) developed asymptomatic grade 2
neutropenia at a dosage of 2.30 mg/m2 (N=3) and
2.60 mg/m2 (N=1). As their subsequent scheduled
dose of vinblastine was delayed, these four dogs were
dose-reduced. Two dogs (5%) developed asymp-
tomatic grade 3 neutropenia at a dose of 2.30 mg/m2:
one dog was dose-reduced, while the remaining dog
also had concurrent grade 3 thrombocytopenia but
stopped VPP due to progressive disease. One dog
(2%) developed grade 3 neutropenia at a dosage of
3.00 mg/m2 and required prophylactic antibiotics.
Four dogs (12%) developed febrile grade 4 neu-
tropenia. Out of these four dogs, one died following
acute respiratory distress and upper airway obstruc-
tion approximately 10 days following vinblastine
administered at a reduced dosage of 2.20 mg/m2; the
neutrophil count had recovered at the time of respi-
ratory distress. This dog had previously required a
dose reduction after developing grade 3 neutropenia
at a dosage of vinblastine of 2.30 mg/m2 and was
being slowly escalated with 5% increase intervals.
Post-mortem examination was consistent with pha-
ryngeal oedema and inflammation as well as necro-
suppurative pneumonia and disseminated
intravascular coagulation (DIC). This dog completed
definitive intent RT 12 days prior to developing feb-
rile neutropenia, however, the pharynx and larynx
Table 4. Chemotherapy-induced toxicity at various dosage levels. Rows with text in bold represent the intended dosage in the VPP protocol
at initiation. Alternative dosages represent dogs that required dosage reductions due to dose-limiting toxicities
Dose Number administered
(220 total)
Number of Grade
1 or 2 toxicities (%*)
Number of Grade
3 toxicities (%*)
Number of Grade
4 toxicities (%*)
2.00 mg/m2 2 0 (0%) 0 (0%) 0 (0%)
2.10 mg/m2 4 0 (0%) 0 (0%) 0 (0%)
2.20 mg/m2 2 0 (0%) 0 (0%) 1 (50%)
2.30 mg/m2 43 3 (7.0%) 3 (7.0%)† 0 (0%)
2.40 mg/m2 5 1 (20%) 0 (0%) 0 (0%)
2.50 mg/m2 1 0 (0%) 0 (0%) 0 (0%)
2.60 mg/m2 29 4 (13.8%) 0 (0%) 3 (10.3%)†
2.70 mg/m2 5 1 (20%) 0 (0%) 0 (0%)
2.80 mg/m2 3 0 (0%) 0 (0%) 0 (0%)
2.90 mg/m2 2 1 (50%) 0 (0%) 0 (0%)
3.00 mg/m2 124 9 (7.2%) 1 (0.8%) 1 (0.8%)
*Percentages calculated as the number of toxicities per dosage divided by the total number of doses administered at that dosage multiplied
by 100. †One dog in each group developed concurrent toxicities of the same grade, and thus were counted as two separate instances.
© 2016 The Authors. Veterinary Medicine and Science Published by John Wiley & Sons Ltd.
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were not in the irradiated field. One dog with febrile
grade 4 neutropenia and concurrent grade 4 throm-
bocytopenia 5 days following vinblastine at 2.60 mg/
m2 was euthanized on presentation, as the client
declined supportive treatment. The remaining two
dogs with febrile neutropenia recovered following
24 h of supportive care: one dog had received a
dosage of 2.60 mg/m2, while the other had received
3.00 mg/m2. Three of the four dogs with grade 4 neu-
tropenia underwent concurrent RT upon starting
VPP chemotherapy: only one dog developed neu-
tropenia while undergoing RT; the other two dogs
had completed RT a minimum of 14 days prior.
None of the other dogs receiving RT developed any
DLT. Asymptomatic grade 4 neutropenia was not
detected in any dog, although a CBC was only con-
sistently performed at the expected nadir in 12 out of
27 dogs that received more than three doses. In the
latter half of the protocol, one dog developed grade
3 neutropenia, while a second dog developed grade 4
neutropenia following vinblastine administered at
3.00 mg/m2 even though both dogs had previously
tolerated 3.00 mg/m2 at days 14 and 21.
Low-grade myelosuppression and gastrointestinal
toxicity were common. Twenty dogs (58%) devel-
oped grade 1 neutropenia at a range of dosages
(2.30–3.00 mg/m2), and two dogs (5%) developed
grade 2 neutropenia that did not disrupt the dose
intensity of the protocol as the neutrophil count
recovered by the time of the next scheduled dose of
vinblastine. Grade 1 thrombocytopenia occurred in
seven dogs (20%) at dosages ranging from 2.10 to
3.00 mg/m2 and one dog developed grade 2 thrombo-
cytopenia following vinblastine administered at
2.60 mg/m2. None of these toxicities affected dose
intensity. No gastrointestinal DLT was recorded,
however, 10 dogs (29%) developed at least one epi-
sode of grade 1 or 2 gastrointestinal toxicity during
the protocol. Five dogs developed multiple episodes
of gastrointestinal toxicity at various vinblastine
dosages (2.30–3.00 mg/m2). One dog developed one
episode of grade 2 anorexia (2.30 mg/m2), two epi-
sodes of grade 2 diarrhoea and anorexia (both at
3.00 mg/m2) and one episode of grade 2 diarrhoea
(at 2.9 mg/m2). Despite the lack of conventional gas-
trointestinal DLT, this dog was dose-reduced
because the owner considered these adverse effects
unacceptable.
Variables associated with toxicity or tolerability
Univariable analysis (Table 5) for toxicity suggested
that dogs receiving concurrent RT (P = 0.048) and
intact dogs (P = 0.033) were more likely to develop
Table 5. Univariable analysis of factors potentially associated with increased toxicity with VPP and likelihood of tolerability of vinblastine admin-
istered at 3.00 mg/m2 weekly
Grade 3
neutropenia
Grade 4
neutropenia
Increased risk of
dose reduction
Decreased tolerability
of vinblastine 3.00 mg/m2 weekly
administered once
Age 0.042* 0.872 0.074* 0.179*
Weight 0.172* 0.748 0.127* 0.155*
Sex 0.230 0.604 0.152* 0.446
Neutered 0.128* 0.033* 1.000 0.648
Patnaik Grade
(2 vs. 3)
0.249 1.000 0.362 0.41
Kiupel
(High vs. Low)
0.561 1.000 0.459 0.699
Margin (incomplete) 1.000 0.126* 0.696 0.244
MI
(>5)
0.156* 1.000 0.074* 0.185*
Radiation therapy 1.000 0.048* 1.000 1.000
Representative P-values are shown (Fisher’s exact test). *variables selected for subsequent multi-variable analysis. Values in bold indicate
P < 0.05.
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grade 4 neutropenia, while younger dogs (P = 0.042)
were more likely to develop grade 3 neutropenia.
On multi-variable analysis, no variables were asso-
ciated with toxicity or tolerability of VPP with the
exception of MI. Dogs with a MI >5 were more likely
to require a dose reduction (P = 0.048 odds ratio
15.9 95% CI 1.44–500.0).
Discussion
The purpose of this study was to evaluate the tolera-
bility of VPP. The demographics and staging of dogs
in this study were similar to other studies evaluating
canine MCTs (White et al. 2011). Intermediate grade
(Patnaik) MCTs were more common in this popula-
tion of dogs but all of the dogs with intermediate
grade MCTs had recurrent or metastatic disease.
Although most dogs included in the study had high-
risk MCT, the low median MI is not surprising, as
this marker lacks sensitivity as a negative prognostic
factor (Lelyveld et al. 2015).
As expected, the DLT in this study was neutrope-
nia. While the primary hypothesis was correct in
fewer than 20% of dogs that developed grade 4 neu-
tropenia, an unexpected finding was that at least
11% of dogs developed grade 4 febrile neutropenia,
which is higher than has been reported in other stud-
ies using lower dosages of vinblastine (0–7%)
(Davies et al. 2004; Rassnick et al. 2008; Thamm
et al. 1999, 2006; Trumel et al. 2005). However, this
compares favourably to the 46% of dogs that devel-
oped grade 4 neutropenia treated with vinblastine at
3.50 mg/m2 every other week, a protocol that carries
similar dose intensity to VPP (Rassnick et al. 2008).
Also surprising was the fact that two dogs (6%) died
following grade 4 febrile neutropenia, although one
of them was euthanized without attempting support-
ive care.
Interestingly, the only two dogs that developed
dose-limiting neutropenia (grade 3 and febrile grade
4 neutropenia) after receiving 3.00 mg/m2 vinblastine
had previously tolerated the same dosage given
weekly. Vinblastine has not been previously reported
in humans or dogs to cause cumulative toxicity;
indeed, some authors have suggested that tolerance
may develop following prior vinblastine drug
exposure (Rowinsky 2011; Vickery et al. 2008). This
study suggests that tolerance is unlikely with two
dogs developing dose-limiting neutropenia in the lat-
ter every other week aspect of the protocol despite
previously tolerating the same vinblastine dosage at
a 7-day interval. This finding highlights the impor-
tance of performing a CBC (or minimally a neu-
trophil count) approximately 6–7 days following
every dose of vinblastine, even if the dosage was pre-
viously well tolerated.
No episodes of gastrointestinal DLT were
reported, however, 29% of dogs developed grade 1
or grade 2 gastrointestinal toxicity during the proto-
col. This rate of gastrointestinal adverse effects is
slightly higher than the rates previously reported (8–
21%) in other studies using the dosage of 2.00 mg/
m2 (Rassnick et al. 2008; Thamm et al. 1999, 2006;
Trumel et al. 2005). The use of the quality-of-life
questionnaire at every visit ensured that owners
reflected and reported on any clinical signs. The rate
reported here was unlikely to have been under-
reported as any adverse gastrointestinal event,
whether witnessed by the clinician or reported by the
client, was attributed to chemotherapy. It is possible
that other reports may have underestimated the rate
of low-grade toxicity if clients were not specifically
queried. Alternatively, it is possible that this study
overestimated gastrointestinal toxicity as not all epi-
sodes of diarrhoea, inappetence or vomiting may
have been related to chemotherapy.
On univariable analysis, dogs that received RT
were at increased risk of grade 4 neutropenia,
although this lost significance in multi-variable analy-
sis. While three dogs (33%) developed grade 4 neu-
tropenia, only one occurred during the radiation
protocol, while two developed 14 days or longer
after completion of RT, following escalated vin-
blastine dosage. When considering the location and
size of the irradiated fields, the three dogs that devel-
oped grade four neutropenia had three of the four
smallest treatment volumes and contained no or min-
imal active marrow sites in adult dogs. The remain-
ing six dogs (67%) that received RT tolerated the
chemotherapy protocol without dosage reductions or
toxicity. Of the 25 dogs that did not receive RT, 25%
required dosage reductions during the protocol even
© 2016 The Authors. Veterinary Medicine and Science Published by John Wiley & Sons Ltd.
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though only one (4%) developed grade 4 neutrope-
nia. Previous studies assessing tolerability of dose-
escalating vinblastine protocols also did not find that
RT was associated with increased risk of toxicity
despite the use of radiation units that may increase
dose to bone (Vickery et al. 2008). Larger number of
dogs would be needed to determine if this is a type II
error on multi-variable analysis. As suggested by
recent literature, RT alone may control some dogs
with locoregional disease for extended periods of
time, thus questioning the utility of systemic therapy
(Baginski et al. 2014; Chaffin & Thrall 2002; Hume
et al. 2011; Schulman 2015). A randomized trial
would be useful to compare adequate local control
with and without adjuvant VPP to assess if
chemotherapy is beneficial in this setting.
Although dogs with a MI >5 were found to be
more likely to require a dose reduction in multi-vari-
able analysis, neither Patnaik nor Kiupel grade were
associated with toxicity or tolerability of VPP. It is
difficult to hypothesise why dogs with high MI would
be more likely to require a dose reduction compared
to dogs with low MI, particularly in the adjuvant set-
ting following local control. As no correction was
made for multiple comparisons, the correlation of
MI >5 and toxicity could be due to a type I error.
To the authors’ knowledge, there are no previous
published studies assessing the tolerability of vin-
blastine given at 3.00 mg/m2 7 days apart. This study
only included administration of 3.00 mg/m2 at day 14
and day 21 before switching to administration of
3.00 mg/m2 every other week. Dose escalation toler-
ability could not be assessed in two dogs due to pro-
gressive disease following the first dose of
vinblastine. Of the remaining 32 dogs, 24 (75%) tol-
erated 3.00 mg/m2 at a 7-day interval at one point in
the protocol, however, two of those dogs required
dose reductions once switching to every other week
administration of the same dosage. Due to the fact
that 26% of dogs required dose reductions, and
almost 10% of dogs discontinued the protocol due to
toxicity, it is unlikely that a vinblastine protocol can
be started at 3.00 mg/m2 and administered weekly
for six doses, as was the authors’ proposal prior to
this study. More importantly, of the DLTs that
occurred, 81% developed following a dosage lower
than 3.00 mg/m2. It is also unlikely based on results
of this study and previous reports, that the dosage
can be systematically further increased without an
associated increase in the rate of grade 4 neutropenia
(Bailey et al. 2008; Rassnick et al. 2008).
One of the reasons to explain the difference in tol-
erability of this protocol among different dogs is the
significant inter-individual variation in the pharma-
cologic behaviour of vinblastine (Beck et al. 1979).
Several attempts were made to model the data col-
lected in order to identify any algorithms that could
predict the ‘ideal’ characteristics to predict tolerabil-
ity of weekly vinblastine at 3.00 mg/m2, but it was
not possible given the small number of dogs. It is
important to emphasise that statistical analysis must
be interpreted with caution given the low numbers
and lack of information on known prognostic factors
for toxicity. This is a limitation of statistical analysis
with only a small number of dogs, however, the goal
was to identify any patterns that could guide further
studies with more robust analysis.
Most chemotherapy dosages for companion ani-
mals and humans are prescribed on the basis of the
patient’s body surface area (BSA), which tends to
correlate poorly with drug pharmacokinetics
(Arrington et al. 1994; Frazier & Price 1998a; Page
et al. 1988; Frazier & Price 1998b; Walko & McLeod
2009). BSA is proportional to blood volume and
glomerular filtration rate, despite that neither con-
tribute to chemotherapy efficacy nor toxicity as much
as liver function or other metabolic variations
(Freireich et al. 1966; Gao et al. 2008; Goldsmith
et al. 1975; Gurney 1996). However, it provides a
method by which the maximum tolerated dose of
many chemotherapy drugs in various species includ-
ing humans, dogs, rats and mice is normalised
(Freireich et al. 1966; Gao et al. 2008; Goldsmith
et al. 1975; Pinkel 1958). To date, there is no clear
relationship between pharmacokinetic parameters
and BSA for common chemotherapy drugs; in some
BSA-calculated doses administered to people, up to
20-fold variation in pharmacokinetics may routinely
occur (Gurney 1996). For drugs like vinblastine that
are metabolised, the use of BSA may not be ideal as
tumour effects and adverse effects are based on com-
plex processes such as metabolism and genetics,
© 2016 The Authors. Veterinary Medicine and Science Published by John Wiley & Sons Ltd.
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making it challenging to develop a system that works
for all dosing (Frazier & Price 1998a; Greek & Rice
2012; Frazier & Price 1998b). Tumour and patient
chemosensitivity variations likely depend on phar-
macokinetic, pharmacodynamic and pharmacoge-
nomic differences, which are early areas of active
research in veterinary medicine. In this particular
group of dogs, multi-drug resistance 1 gene (MDR-1)
polymorphisms and/or concurrent prednisolone
administration may have altered drug disposition
(Sathiapalan & El-Soth 2001).
As previous studies have suggested, myelosuppres-
sion may be predictive of cancer response to
chemotherapy (Sorenmo et al. 2010; Vaughan et al.
2007). Therefore, dogs that do not develop substan-
tial neutropenia may benefit from individual dosage
escalations, even above 3.00 mg/m2, in order to
achieve a lower neutrophil count. An alternative
strategy to further optimise the dose intensity of the
protocol would be to increase dose density. Dose-
dense chemotherapy regimens aim to potentiate
response by decreasing the inter-treatment interval
(Chabner 2011; Norton 1997). The decision to
administer vinblastine every other week after the
fourth treatment was initially empirically extrapo-
lated, and as this drug has not been reported to have
cumulative toxicity and typically causes a neutrophil
nadir between 5 and 7 days after administration,
dogs would be expected to tolerate weekly treat-
ments (Golden & Langston 1988; Rowinsky 2011;
William et al. 1975). Theoretically, Norton’s model
of fractional cell kill supports a benefit from max-
imising dose intensity, and dose intensity optimisa-
tion may reduce hospital visits and shorten the
duration of the protocol (Norton 1997). Both dose
density and administered dosage are known to affect
response of cancer to chemotherapy, and they both
determine the dose intensity of a protocol (Citron
et al. 2003; Frei & Canellos 1980; Loibl et al. 2011).
Dose reductions and dose delays have both shown to
be associated to a more negative outcome in human
patients with cancer (Citron et al. 2003; Loibl et al.
2011). In this study, when toxicity caused dose delay,
the authors preferred to dose-reduce affected dogs,
in order to standardise an approach and ensure toler-
ability for the pet and owner. Notably, dose delays
within an institution may vary from 2 to 7 or more
days depending on the client’s ability to return. Dogs
in this study were dose-reduced in an attempt to
standardise administration time points and enable
more consistent assessment of dose intensity. Grade
2 neutropenias that required dose delay were also
dose-reduced in order to maintain a consistent
schedule, although if dogs were switching to adminis-
tration every 14 days, dose reductions were not nec-
essary. Only 10% dose reductions were performed,
as an attempt to limit any negative effect in treat-
ment efficacy. It is important to reiterate that a
prospective trial is required to definitively determine
if increasing dose intensity or altering dose density
improves efficacy and outcome, particularly as qual-
ity-of-life measures are vital when considering
chemotherapy regimens in pet dogs.
Multiple reports of chemotherapy have suggested
that the use of BSA to calculate chemotherapeutic
doses results in smaller dogs to be overdosed
(Arrington et al. 1994; Frazier & Price 1998a; Page
et al. 1988; Frazier & Price 1998b). Although there
were few dogs weighing less than 10 kg in this study,
they were not at a higher risk of developing toxici-
ties, which correlates well with results in other work
investigating mitotic spindle inhibitors (Bailey et al.
2008). The authors were surprised at the range of
vinblastine dosages that caused DLT and disruption
of the intended protocol. There are obvious flaws in
the use of BSA dosing of chemotherapy in dogs, and
drug regimen design in human pharmacology and
oncology have considered an integrative system to
incorporate pharmacokinetics, pharmacodynamics
and pharmacogenomics (Frazier & Price 1998a; Fra-
zier & Price 1998b; Swen et al. 2011; Walko & Ike-
diobi 2012). While veterinary literature currently
lacks sufficient information regarding pharmacoge-
nomics differences across dog breeds, it may be that
as veterinary knowledge of both genetic and meta-
bolic differences increases, alternative strategies for
chemotherapy dosing may be feasible (Lawrence
et al. 2015).
Overall, this rapid dose-escalating vinblastine-pre-
dnisolone protocol was well tolerated and reported
adverse effects were acceptable. Although there is a
higher rate of toxicity compared to protocols utilising
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a lower dosage of vinblastine, this protocol increases
dose intensity by 45% compared to the conventional
protocol using the static 2.00 mg/m2 dosage protocol,
and a 5% increase over the initial dose-escalating
protocol (Vickery et al. 2008). Toxicity was similar to
that reported in the initial dose escalation protocol
in which of 136 doses administered, 3% resulted in
grade 3 or 4 adverse event (Vickery et al. 2008). Of
220 doses of vinblastine administered, there were
only nine episodes of grade 3 or 4 toxicity (4%) in
this study. Although this was a tolerability study and
dogs with both microscopic and macroscopic disease
were included, the majority of dogs in this study had
microscopic disease that was adequately locally con-
trolled (N = 29), whereas in previous studies, many
dogs had measurable disease (Rassnick et al. 2008;
Thamm et al. 1999). Retrospective comparison
between different protocols is problematic due to
different sample sizes, patient demographics and
response criteria among studies. A prospective ran-
domised trial evaluating a uniform population of
dogs with MCTs with similar histopathologic and
clinical features should be done to compare proto-
cols.
This study had multiple limitations, many of which
have been discussed. It was not a randomised con-
trolled study, therefore historical data were used for
comparison of toxicity and tolerability of VPP and
the conventional protocol using a dosage of 2.00 mg/
m2. As the study was not funded, not all dogs were
treated as per clinician recommendations. Specifi-
cally, one dog was euthanized due to toxicity, and
another dog was dose-reduced despite grade 2 gas-
trointestinal toxicity. During dose escalation, CBCs
were only performed 7 days post-vinblastine admin-
istration and were not consistently performed during
the latter half of the protocol, therefore episodes of
silent grade 4 neutropenia may have been missed.
The detection of non-haematological toxicity was
dependent on owner’s recollection of events, and
therefore, the grading and frequency of toxicity
events could have been under- or overestimated
depending on the owner’s perception. Dogs were
included based on their initial histopathologic report
and review of slides by one pathologist was not per-
formed. As grade was assessed statistically, this may
have influenced the statistical significance. Lastly,
although an effort was made to look for factors pre-
dictive of toxicity, the small number of dogs included
in the study precluded a clinically useful result.
In conclusion, this dose-escalating vinblastine and
prednisolone protocol was well-tolerated overall
with 4% grade 3 or 4 toxicity following administra-
tion of 220 doses of vinblastine. Of the 34 dogs
included, 70% tolerated 3.00 mg/m2 given 7 days
apart at days 14 and 21 and 68% completed the pro-
tocol; 26% of the dogs required dose reductions and
8% discontinued VPP due to toxicity. It is unlikely
that vinblastine can be started at 3.00 mg/m2 weekly
without incurring unacceptable rates of toxicity.
Optimisation of vinblastine dose intensity may be
achieved by reducing the inter-treatment interval or
by identifying those dogs that can safely be treated
with higher dosages. Further investigation to deter-
mine if dose intensity is linked to outcome in high-
risk canine MCTs is necessary.
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